Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARCELO VAILATI NEGRAO

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1376070300
CMS profile
4003636
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$149.43

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $149.43 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Genentech, Inc. $149.43 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARCELO VAILATI NEGRAO

NPI 1376070300 · CMS profile ID 4003636

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARCELO VAILATI NEGRAO, NPI 1376070300, CMS profile ID 4003636, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1376070300?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $149.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech, Inc. $149.4306/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950660457 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $149.43 1
PY2023 $4,089.41 6
PY2024 $10,943.96 11
PY2025 $3,536.66 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,846.52 6
PY2025 Principal investigator $2,059,899.37 28
PY2024 Recipient $4,470.00 3
PY2024 Principal investigator $3,036,066.58 21
PY2023 Recipient $3,547.90 2
PY2023 Principal investigator $2,419,476.23 22
PY2022 Recipient $353.00 1
PY2022 Principal investigator $864,167.42 17
PY2021 Principal investigator $1,014,815.80 49
PY2020 Principal investigator $1,405,196.16 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $50,420.00 12/05/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563195
Principal investigator 1 Genentech, Inc. $11,280.00 11/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563191
Recipient PFIZER INC. $3,200.00 11/03/2025 Covered Recipient Physician SIGVOTATUG VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804536
Principal investigator 1 Genentech, Inc. $79,642.00 10/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563182
Principal investigator 1 Genentech, Inc. $14,315.00 10/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563178
Recipient F. Hoffmann-La Roche AG $278.26 10/23/2025 Covered Recipient Physician NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211537519
Recipient F. Hoffmann-La Roche AG $278.26 10/23/2025 Covered Recipient Physician NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211537522
Principal investigator 1 Genentech, Inc. $1,688.00 10/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563187
Recipient PFIZER INC. $940.00 10/19/2025 Covered Recipient Physician BINIMETINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804531
Principal investigator 1 PFIZER INC. $23,590.88 09/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228712224
Principal investigator 1 PFIZER INC. $47,181.76 09/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228712422
Principal investigator 1 Eli Lilly and Company $566.00 08/26/2025 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187886082
Recipient PFIZER INC. $1,820.00 08/22/2025 Covered Recipient Physician DACOMITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804523
Principal investigator 1 Genentech, Inc. $16,498.00 07/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563165
Principal investigator 1 Genentech, Inc. $2,669.00 05/29/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563150
Principal investigator 1 Genentech, Inc. $13,921.00 05/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563161
Principal investigator 1 Genentech, Inc. $24,500.00 05/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563157
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENCORAFENIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228837710
Principal investigator 1 Mirati Therapeutics, Inc. $35,754.92 05/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236529892
Principal investigator 1 Genentech, Inc. $7,918.00 04/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
NAUTIKA1 previously LCMC4 No dispute reported 06/30/2026 1211563154
Principal investigator 1 ARRAY BIOPHARMA INC $12,557.50 03/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228843585
Principal investigator 1 ARRAY BIOPHARMA INC $8,301.75 03/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228845590
Principal investigator 1 ARRAY BIOPHARMA INC $1,406.25 03/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228846605
Principal investigator 1 ARRAY BIOPHARMA INC $8,764.47 03/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228846617
Principal investigator 1 Mirati Therapeutics, Inc. $56,004.90 02/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236529888
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 02/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228845606
Principal investigator 1 ARRAY BIOPHARMA INC $16,983.00 02/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228846609
Principal investigator 1 ARRAY BIOPHARMA INC $7,500.00 02/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228846661
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,159.91 02/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation No dispute reported 06/30/2026 1190294331
Principal investigator 1 Eli Lilly and Company $5,831.54 01/27/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187875031
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $172,376.56 01/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Trial of MRTX849 in Combination with ABI-009 in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer with KRAS G12C Mutation No dispute reported 06/30/2026 1235999495
Principal investigator 1 AstraZeneca Pharmaceuticals LP $960,301.93 01/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase II trial of PARP inhibition, radiation, and immunotherapy in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial No dispute reported 06/30/2026 1185538012
Principal investigator 1 Eli Lilly and Company $434,857.00 01/07/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187873501
Principal investigator 1 Novartis Pharmaceuticals Corporation $910.00 01/01/2025 Non-covered Recipient Entity
UT MD ANDERSON CANCER CENTER CLINICAL CANCER PREVENTION
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation No dispute reported 06/30/2026 1190308980